Teva Pharmaceutical Industries Limited · TASE:TEVA

Teva Pharmaceutical Industries — Merger or Acquisition (March 2011)

25 slides from Teva Pharmaceutical Industries's merger presentation, Mar 24, 2011

  1. Slide 1: The Future of Consumer Health Care

    The Future of Consumer Health Care

  2. Slide 2: Coming Together To Lead The Consumer Health Care Industry

    Coming Together To Lead The Consumer Health Care Industry 2

  3. Slide 3: Creating a New Business Model in Consumer Health Care

    Creating a New Business Model in Consumer Health Care 3

  4. Slide 4: Serve More Consumers in More Parts of the World

    Serve More Consumers In More Parts of the World, More Completely… Better Technology Better and High Accessibility Quality More Broader Channels Portfolio of Products Geographic Expansion …by increasing access to high-quality, affordable OTC medicines 4

  5. Slide 5: Consumer Health Care Partnership

    Consumer Health Care Partnership  Joint Venture for OTC businesses outside North America  Teva to take global manufacturing responsibility  Global collaboration on new product development and new brand creation, including North America 5

  6. Slide 6: Megatrends: Demographic aging population

    Consumer Health Care Partnership Nearly $200B Global Market* Demographic MEGATRENDS aging population *estimated global retail sales 6

  7. Slide 7: Megatrends: Focus on wellness

    Consumer Health Care Partnership Nearly $200B Global Market* Demographic MEGATRENDS aging focus on population wellness *estimated global retail sales 7

  8. Slide 8: Megatrends: Consumer involvement and purchasing power

    Consumer Health Care Partnership Nearly $200B Global Market* Demographic MEGATRENDS consumer aging focus on involvement population wellness & purchasing power *estimated global retail sales 8

  9. Slide 9: OTC Products Offer Untapped Growth Potential

    OTC Products Offer Untapped Growth Potential 9

  10. Slide 10: Building Consumer Health Brands

    Building Consumer Health Brands Potential Rx-to-OTC Switches and New Trusted Brands 10

  11. Slide 11: Coming Together to Accelerate Growth!

    Coming Together to Accelerate Growth! 11

  12. Slide 12: Creating a New Business Model

    Creating a New Business Model in Consumer Health Care Unique partnership First of its kind in the industry Best-in-class joint capabilities 12

  13. Slide 13: Industry Leading Capabilities

    Industry Leading Capabilities No. 1 generic pharmaceutical company Top 15 global pharmaceutical company 63 billion tablets manufactured in 2010 Operations in 60 countries Distribution of products to over 100 markets Global product portfolio of nearly 1,500 molecules 13

  14. Slide 14: Industry Leading Capabilities: Development, Production and Pharmacy Coverage

    Industry Leading Capabilities  Leading capabilities in development, registration, production & selling of medicines  Pharmacy channel coverage 14

  15. Slide 15: Industry Leading Capabilities: Brand-Building

    Industry Leading Capabilities  Core capabilities in brand-building, consumer-led innovation and mass trade retailing  Leading consumer and pharmacist-recognized brands  World’s top advertiser 15

  16. Slide 16: Industry Leading Capabilities: Consumer Innovation

    Industry Leading Capabilities  Core capabilities in brand-building, consumer-led innovation and mass trade retailing  Consumer products innovation leadership 16

  17. Slide 17: Industry Leading Market Reach

    Industry Leading Market Reach  P&G - excellence with mass/grocery channels and high-frequency stores in developed and developing markets  Teva - pharmacy channel coverage 17

  18. Slide 18: World's Leading Seller of Medicines and Brand-Builder Coming Together

    World’s Leading Seller of Medicines and World’s Leading Brand-Builder Coming Together Powerful Combination  Global portfolio of leading brands  Strong global footprint  Best in class consumer understanding Teva  Brand-building & advertising scale P&G  Low cost & high quality manufacturing  Unm

  19. Slide 19: >$1bn JV Sales: Immediate Scale

    Consumer Health Care Partnership Immediate Scale >$1bn JV Sales 19

  20. Slide 20: Growth Plans

    Consumer Health Care Partnership Growth Plans  Leveraging our strong positions in emerging markets  Developing new trusted brands 20

  21. Slide 21: Growth Plans: Projecting $4bn Sales

    Consumer Health Care Partnership Growth Plans  Outpacing OTC market growth $4bn  Projecting sales of $4bn in the coming years  Potential upside: Global market growth $1bn and robust pipeline of Rx-to-OTC switches 21

  22. Slide 22: The Future of Consumer Health Care: Key Points

    The Future of Consumer Health Care Key Points  A win for both companies  Ideal partnership creates new business model for industry  Enables both companies to generate greater value  A win for consumers around the world  Expected closing - Fall 2011 22

  23. Slide 23: The Future of Consumer Health Care

    The Future of Consumer Health Care 23

  24. Slide 24: P&G Forward Looking Statement

    P&G Forward Looking Statement All statements, other than statements of historical fact included in this release or presentation, are forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on financial data, market assump

  25. Slide 25: Teva Forward Looking Statement

    Teva Forward Looking Statement This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could c

Teva Pharmaceutical Industries — Merger or Acquisition (March 2011) on 6ix